NOVAST

301569
17.244.17% ( -0.75 )
Delay Closed: Nov 16, 15:00:00

Valuation

Current ValuationThe current P/E ratio is 49.39, below the reasonable range, cheaper than 95.65% of the time in the past 1 years, and the industry ranks 105/222, the industry Median 22.19.

49.39xP/E
Stock price¥17.24Earnings per share¥0.35

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 22.19x
015304560

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 22.19x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
600436SHZZPZH
59.62x17.36%¥78.51B
002653SZHaisco
48.63x572.55%¥63.39B
002821SZAsymchem
43.83x16.47%¥51.91B
300765SZCSPC Innovation
46.24x628.47%¥45.90B
002294SZSalubris
46.03x29.31%¥32.91B
300199SZHYBIO
48.42x--¥19.46B
603858SHBUCHANG PHARMA
56.02x--¥15.79B
301569SZNOVAST
49.39x--¥15.37B
002626SZKingdomway
43.61x26.67%¥10.16B
300725SZPHARMABLOCK
45.32x18.18%¥10.04B
600851SHHX GROUP
51.45x--¥9.83B
600789SHLKPC
52.53x--¥7.16B
688553SHHUIYU PHARMACEUTICAL
49.72x--¥6.42B
688799SHHWPC
51.27x24.46%¥5.84B
002390SZxinbang phar.
41.58x--¥5.75B
301393SZHighfine
46.41x--¥5.72B
002907SZPharscin Pharma
56.52x--¥5.30B
002940SZALK
41.02x--¥4.53B
301281SZKeyuan Pharma
54.97x--¥3.87B
300584SZHicin Pharmaceutical
48.90x--¥3.50B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.